Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial

BACKGROUND: Mevidalen is a selective positive allosteric modulator (PAM) of the dopamine D1 receptor subtype. OBJECTIVE: To assess the safety and efficacy of mevidalen for treatment of cognition in patients with Lewy body dementia (LBD). METHODS: PRESENCE was a phase 2, 12‐week study in participants...

Descripción completa

Detalles Bibliográficos
Autores principales: Biglan, Kevin, Munsie, Leanne, Svensson, Kjell A., Ardayfio, Paul, Pugh, Melissa, Sims, John, Brys, Miroslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300146/
https://www.ncbi.nlm.nih.gov/pubmed/34859493
http://dx.doi.org/10.1002/mds.28879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300146/
https://www.ncbi.nlm.nih.gov/pubmed/34859493
http://dx.doi.org/10.1002/mds.28879

Ejemplares similares